DAWN Stock Summary and Trading Ideas (Day One Biopharmaceuticals | NASDAQ:DAWN)

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Day One Biopharmaceuticals trades on the NASDAQ stock market under the symbol DAWN.

As of May 3, 2024, DAWN stock price declined to $17.17 with 1,121,807 million shares trading.

DAWN has a beta of 1.66, meaning it tends to be more sensitive to market movements. DAWN has a correlation of 0.14 to the broad based SPY ETF.

DAWN has a market cap of $1.50 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that DAWN belongs to (by Net Assets): VTI, XBI, IWM, VXF, VB.

DAWN stock has underperformed the market in the last year with a return of +20.8%, while SPY returned +27.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DAWN shares. However, DAWN has outperformed the market in the last 3 month and 2 week periods, returning +15.1% and +14.8%, while SPY returned +3.7% and +3.3%, respectively. This indicates DAWN has been having a stronger performance recently.

DAWN support price is $16.64 and resistance is $18.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DAWN stock will trade within this expected range on the day.